Epicrispr raises $90 million Series C after promising early data on epigenetic FSHD therapy
read at Endpoints ↗DealPositive
Epicrispr Biotechnologies announced a $90 million Series C financing round to advance its research program.
The company shared early data suggesting that an epigenetic approach could address facioscapulohumeral muscular dystrophy, a rare muscle-wasting disease.
The new capital will be used to further develop the epigenetic therapy and support additional preclinical and clinical work.
The funding round highlights strong investor confidence in Epicrispr's innovative strategy for treating rare muscular disorders.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Epicrispr secures $90M after early data on epigenetic FSHD treatment”
read at Endpoints ↗86 words · retrieved Aug 11
comments(0)
5-min edit window · permanent after that